GeoVax Labs, Inc. (Nasdaq: GOVX) announced today that Chairman and Chief Executive Officer David Dodd will participate in Tribe Public's CEO Presentation and Q&A Webinar Event titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy.” The webinar is scheduled for 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time on Thursday, May 28, 2026.
“Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches,” said David Dodd. “GeoVax is focused on advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and help address critical gaps in domestic and global biodefense infrastructure.”
The discussion is expected to cover the growing importance of platform-based vaccine technologies in infectious disease preparedness, why emerging outbreaks continue to expose vulnerabilities in global response infrastructure, the potential applicability of MVA-based technologies across multiple viral threats including orthopox and hemorrhagic fever viruses, and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. Its priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity.
To register for the complimentary Zoom webinar event, visit Ebola-May-2026.TribePublic.com. Once registered, participants may begin submitting questions for GeoVax management to Tribe Public at research@tribepublic.com or submit questions during the live webinar using Zoom’s chat feature. Tribe Public Managing Member John F. Heerdink, Jr. will host the event and moderate audience questions.
This announcement underscores the growing urgency for broad-spectrum pandemic preparedness. The recent emergence of Hantavirus concerns, alongside ongoing threats from Ebola, Marburg, and Mpox, highlights the limitations of single-pathogen strategies. GeoVax's MVA-based platform technology could offer a more flexible and scalable approach, potentially reshaping how governments and global health organizations stockpile vaccines and respond to outbreaks. For leaders in business and technology, this represents a shift toward platform-based solutions that could reduce development timelines and manufacturing bottlenecks in future health crises.
Forward-looking statements in this release are based on current expectations and projections. Actual results may differ materially due to various factors, including those detailed in GeoVax's filings with the SEC.
